|
|
Article: Changing CytRx Licenses Broad RNAi Technology From U-Mass.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
CytRx Corp. is changing by taking up the torch of RNA interference technology through license agreements with the University of Massachusetts Medical School.
Although CytRx, of Los Angeles, has experience in gene therapy and gene-based vaccines through its TranzFect technology and in sickle cell disease through Flocor, Steven Kriegsman, CytRx CEO, said his company has "been studying the RNAi area since it started to be discovered and we know that [UMMS] had probably the broadest platform of RNA technology in the world."
RNAi as a platform has been hot lately, gaining favor among academics and companies alike, so much ...
Related newspaper, magazine, and journal articles:
|
|
Article: CytRx Appoints Gregory R. Liberman as General Counsel and ...
PR Newswire;
March 15, 2004 ;
700+ words
... ... responsible for managing CytRx's worldwide legal affairs ... Reporting to Steven A. Kriegsman, Chief Executive Officer ... that Greg has joined CytRx," said Kriegsman. "His diversity of ... and better positions CytRx for success." Liberman ...
|
|